+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Canada Inflammatory Bowel Disease (IBD) Market 2019-2025

  • PDF Icon


  • February 2020
  • Region: Canada
  • Orion Market Research Private Limited
  • ID: 5116709
Canada Inflammatory Bowel Disease (IBD) Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis and Crohn’s Disease), By Diagnostics (Blood & Stool Tests, Endoscopies, Ultrasound, and X-Ray), By Therapeutics (Surgery and Anti- Inflammatory Drug Administration) and Forecast 2019-2025.

The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease, 120,000 with ulcerative colitis, and 15,000 with IBD type unclassified (IBD-U). CCC further estimates that seven out of every 1,000 Canadians has IBD. Moreover, by 2030, the number of people living with IBD is expected to rise to over 400,000, or nearly 1% of the population. The highest reported incidence of IBD is in Nova Scotia at 54.6 per 100,000 new cases per year, and the lowest is in British Columbia at 18.7 per 100,000 people per year. The incidence of IBD in Alberta, Manitoba, Ontario, Quebec, and Saskatchewan are similar, ranging from 21.6 to 28.3 per 100,000 people per year.

Canada IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. Canada IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

The companies which are contributing to the growth of the Canada IBD market include Abbott Laboratories, AbbVie Inc., Accesa Labs, Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Laboratory Corporation of America Holdings, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology:

The market study of Canada IBD market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

Market Segmentation:

1. Canada IBD Market Research and Analysis by Disease Type
2. Canada IBD Market Research and Analysis by Diagnostics
3. Canada IBD Market Research and Analysis by Therapeutics

The Report Covers:
  • Comprehensive Research Methodology of the Canada IBD market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Canada IBD market.
  • Insights about market determinants which are stimulating the Canada IBD market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • AbbVie Inc.
  • Accesa Labs
  • Boehringer Ingelheim International GmbH
  • Celgene Corp.
  • Eli Lilly and Co.
  • Johnson & Johnson Services Inc.
  • Laboratory Corporation of America Holdings
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda pharmaceutical Co., Ltd.